CramonP, WintherKH, WattT, BonnemaSJ, BjornerJB, EkholmO, GroenvoldM, HegedüsL, Feldt-RasmussenU, Rasmussen ÅK 2016. Quality-of-life impairments persist six months after treatment of Graves' hyperthyroidism and toxic nodular goiter: a prospective cohort study. Thyroid, 26:1010–1018.
2.
SawinCT, GellerA, WolfPA, BelangerAJ, BakerE, BacharachP, WilsonP, BenjaminEJ, D'AgostinoRB. 1994. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med, 331:1249–1252.
3.
ChenQ, YanY, ZhangL, ChengK, LiuY, ZhuW. 2014. Effect of hyperthyroidism on the hypercoagulable state and thromboembolic events in patients with atrial fibrillation. Cardiology, 127:176–182.
BiondiB. 2012. Mechanisms in endocrinology: heart failure and thyroid dysfunction. Eur J Endocrinol, 167:609–618.
6.
PetersA, EhlersM, BlankB, ExlerD, FalkC, KohlmannT, Fruehwald-SchultesB, WellhoenerP, KernerW, FehmHL. 2000. Excess triiodothyronine as a risk factor of coronary events. Arch Intern Med, 160:1993–1999.
7.
SundareshV, BritoJP, WangZ, ProkopLJ, StanMN, MuradMH, BahnRS. 2013. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab, 98:3671–3677.
8.
BurchHB, CooperDS. 2015. Management of Graves disease: a review. JAMA, 314:2544–2554.
9.
BartalenaL, FatourechiV. 2014. Extrathyroidal manifestations of Graves' disease: a 2014 update. J Endocrinol Invest, 37:691–700.
10.
TarantiniB, CiuoliC, Di CairanoG, GuarinoE, MazzucatoP, MontanaroA, BurroniL, VattimoAG, PaciniF. 2006. Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism. J Endocrinol Invest, 29:594–598.
11.
SosaJA, MehtaPJ, WangTS, BoudourakisL, RomanSA. 2008. A population-based study of outcomes from thyroidectomy in aging Americans: at what cost?. J Am Coll Surg, 206:1097–1105.
12.
RossDS, BurchHB, CooperDS, GreenleeMC, LaurbergP, MaiaAL, RivkeesSA, SamuelsM, SosaJA, StanMN, WalterMA. 2016. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid, 26:1343–1421.
13.
ElfenbeinDM, SchneiderDF, HavlenaJ, ChenH, SippelRS. 2015. Clinical and socioeconomic factors influence treatment decisions in Graves' disease. Ann Surg Oncol, 22:1196–1199.
14.
BurchHB, BurmanKD, CooperDS. 2012. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab, 97:4549–4558.
15.
BritoJP, PayneS, OspinaNS, Rodriguez-GutierrezR, MarakaS, SangaralinghamLR, Iñiguez-ArizaNM, MontoriVM, StanMN. 2020. Patterns of use, efficacy, and safety of treatment options for patients with Graves' disease: a nationwide population-based study. Thyroid, 30:357–364.
16.
WartofskyL, GlinoerD, SolomonB, NagatakiS, LagasseR, NagayamaY, IzumiM. 1991. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid, 1:129–135.
17.
SundareshV, BritoJP, ThapaP, BahnRS, StanMN. 2017. Comparative effectiveness of treatment choices for Graves' hyperthyroidism: a historical cohort study. Thyroid, 27:497–505.
18.
BartalenaL, BurchHB, BurmanKD, KahalyGJ. 2016. A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol, 84:115–120.
19.
CarellaC, MazziottiG, SorvilloF, PiscopoM, CioffiM, PillaP, NersitaR, IorioS, AmatoG, BravermanLE. 2006. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid, 16:295–302.
20.
LaurbergP, WallinG, TallstedtL, Abraham-NordlingM, LundellG, TorringO. 2008. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol, 158:69–76.
21.
CappelliC, GandossiE, CastellanoM, PizzocaroC, AgostiB, DelbarbaA, PirolaI, De MartinoE, RoseiEA. 2007. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. Endocr J, 54:713–720.
22.
YoshiharaA, NohJ, YamaguchiT, OhyeH, SatoS, SekiyaK, KosugaY, SuzukiM, MatsumotoM, KuniiY. 2012. Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab, 97:2396–2403.
23.
FranksP, ClancyCM, GoldMR. 1993. Health insurance and mortality: evidence from a national cohort. JAMA, 270:737–741.
24.
HadleyJ. 2003. Sicker and poorer—the consequences of being uninsured: a review of the research on the relationship between health insurance, medical care use, health, work, and income. Med Care Res Rev, 60:3S–75S.
25.
LemaireA, CookC, TackettS, MendesDM, ShortellCK. 2008. The impact of race and insurance type on the outcome of endovascular abdominal aortic aneurysm (AAA) repair. J Vasc Surg, 47:1172–1180.
26.
BoxerLK, DimickJB, WainessRM, CowanJA, HenkePK, StanleyJC, UpchurchGRJr. 2003. Payer status is related to differences in access and outcomes of abdominal aortic aneurysm repair in the United States. Surgery, 134:142–145.
27.
MetsoS, AuvinenA, HuhtalaH, SalmiJ, OksalaH, JaatinenP. 2007. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer, 109:1972–1979.
28.
KitaharaCM, Berrington de GonzalezA, BouvilleA, BrillAB, DoodyMM, MeloDR, SimonSL, SosaJA, TulchinskyM, VilloingD, PrestonDL. 2019. Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med, 179:1034–1042.
29.
AsbanA, AnueA, XieR, ChenH. 2020. Increasing use of thyroidectomy as definitive treatment for hyperthyroidism. J Surg Res, 246:435–441.
30.
LiuJ, BargrenA, SchaeferS, ChenH, SippelRS. 2011. Total thyroidectomy: a safe and effective treatment for Graves' disease. J Surg Res, 168:1–4.
31.
AllannicH, FauchetR, OrgiazziJ, OrgiazziAM, GenetetB, LorcyY, GuerrierAL, DelambreC, DerennesV. 1990. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab, 70:675–679.
32.
MasielloE, VeronesiG, GalloD, PremoliP, BianconiE, RosettiS, CusiniC, SabatinoJ, IppolitoS, PiantanidaE. 2018. Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest, 41:1425–1432.
33.
VosXG, EndertE, ZwindermanAH, TijssenJGP, WiersingaWM. 2016. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab, 101:1381–1389.
34.
StrujaT, KaeslinM, BoesigerF, JutziR, ImahornN, KutzA, BernasconiL, MundwilerE, MuellerB, Christ-CrainM. 2017. External validation of the GREAT score to predict relapse risk in Graves' disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol, 176:413–419.
35.
GronichN, LaviI, RennertG, SalibaW. 2020. Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study. Thyroid, 30:243–250.
36.
FranklynJA, MaisonneuveP, SheppardM, BetteridgeJ, BoyleP. 1999. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet, 353:2111–2115.
37.
HieuTT, RussellAW, CuneoR, ClarkJ, KronT, HallP, DoiSAR. 2012. Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis. Endocr Relat Cancer, 19:645–655.
38.
PesceCE, ShiueZ, TsaiH-L, UmbrichtCB, TufanoRP, DackiwAPB, KowalskiJ, ZeigerMA. 2010. Postoperative hypocalcemia after thyroidectomy for Graves' disease. Thyroid, 20:1279–1283.
39.
Chomsky-HigginsKH, RochefortHM, SeibCD, GosnellJE, ShenWT, DuhQ-Y, SuhI. 2018. Recombinant parathyroid hormone versus usual care: do the outcomes justify the cost?. World J Surg, 42:431–436.
40.
AstorMC, LøvåsK, DebowskaA, EriksenEF, EvangJA, FossumC, FougnerKJ, HolteSE, LimaK, MoeRB. 2016. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab, 101:3045–3053.
41.
OkosiemeOE, TaylorPN, EvansC, ThayerD, ChaiA, KhanI, DramanMS, TennantB, GeenJ, SayersA. 2019. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol, 7:278–287.
